New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07225933 |
A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System |
ACTIVE_NOT_RECRUITING | |
| NCT06517628 |
The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study |
RECRUITING | |
| NCT03382158 |
International PPB/DICER1 Registry |
RECRUITING |
